Logo Mark
Publications

Non-clinical Imetelstat

All Publications

Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia

ImetelstatNon-clinical Imetelstat
Nature Cancer 2023

Bruedigam, et. al.

Telomerase-targeted therapies in myeloid malignancies

Clinical Imetelstat: MDSImetelstatNon-clinical ImetelstatNon-clinical Imetelstat: MF
Blood Advances 2023

Waksal, et. al.

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

ImetelstatNon-clinical Imetelstat
ASH 2022

Bruedigam C, et al.

Pharmacological Inhibitory Effect of Imetelstat, A Novel Human Telomerase Inhibitor in Diffuse Large B-cell Lymphoma and Peripheral T-Cell Lymphoma

ImetelstatNon-clinical Imetelstat
Blood 2022

Aradhya A, et al.

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts

ImetelstatNon-clinical Imetelstat
Journal of Clinical Medicine 2022

Barwe, et al.

Imetelstat Inhibits Telomerase and Prevents Propagation of ADAR1-Activated Myeloproliferative Neoplasm and Leukemia Stem Cells

ImetelstatNon-clinical Imetelstat
ASH 2020

Ma, et al.

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Clinical Imetelstat: MFImetelstatNon-clinical Imetelstat
ASH 2019

Wang, X, et al.

Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

ImetelstatNon-clinical Imetelstat
ASH 2017

Hu C, et al.

Telomerase Inhibition Impairs Self-Renewal of b-Catenin Activated Myeloproliferative Neoplasm Progenitors

ImetelstatNon-clinical Imetelstat
ASH 2017

Ma W, et al.

Integrated Molecular Analysis Identifies Replicative Stress as Sensitizer to Imetelstat Therapy in AML

ImetelstatNon-clinical Imetelstat
ASH 2017

Bruedigam C, et al.

[facetwp facet="publication_load_more"]